76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
AstraZeneca PLC
Closed
SectorHealthcare
11,132 -1.83
Overview
Share price change
24h
Min
11068
Max
11132
Income | 1.3B 2.9B |
|---|---|
Sales | -1.3B 14B |
P/E Sector Avg | 29.321 40.048 |
Dividend yield | 2.87 |
Profit margin | 21.46 |
Employees | 94,300 |
EBITDA | 648M 5.1B |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +20.74% upside |
Dividend yield Sector Avg | 2.87% 2.45% |
|---|---|
Next Dividend date | 8 Sept 2025 |
Next Ex Dividend date | 7 Aug 2025 |
Market Cap | -15B 167B |
|---|---|
Previous open | 11133.83 |
Previous close | 11132 |
AstraZeneca PLC Chart
Past performance is not a reliable indicator of future results.
Related News
AstraZeneca PLC Forecast
Price Target
By TipRanks
20.74% upside
12 Months Forecast
Average 13,406.92 GBX 20.74%
High 16,500 GBX
Low 10,900 GBX
Based on 12 Wall Street analysts offering 12 month price targets forAstraZeneca PLC - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.